Cargando…

B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients

BACKGROUND: B cell depletion with rituximab (RTX) is approved for treatment of rheumatoid arthritis (RA) and ANCA-associated vasculitides (AAV). Recently, RTX has been shown to be effective in AAV maintenance therapy, but an optimal RTX treatment schedule is unknown and the time to B cell repopulati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thiel, Jens, Rizzi, Marta, Engesser, Marie, Dufner, Ann-Kathrin, Troilo, Arianna, Lorenzetti, Raquel, Voll, Reinhard E., Venhoff, Nils
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437549/ https://www.ncbi.nlm.nih.gov/pubmed/28521808 http://dx.doi.org/10.1186/s13075-017-1306-0

Ejemplares similares

Impact of Rituximab on Immunoglobulin Concentrations and B Cell Numbers after Cyclophosphamide Treatment in Patients with ANCA-Associated Vasculitides
por: Venhoff, Nils, et al.
Publicado: (2012)

Mitochondrial DNA: a novel indicator of active inflammation in ANCA-associated vasculitides
por: Giaglis, Stavros, et al.
Publicado: (2023)

JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an in-vitro B cell differentiation model and in patients with rheumatoid arthritis
por: Frede, Natalie, et al.
Publicado: (2023)

B cell depletion by Rituximab severely reduces immunoglobulin levels in patients with ANCA-associated vasculitis previously treated with cyclophosphamide
por: Thiel, Jens, et al.
Publicado: (2011)

Blood CD3-(CD56 or 16)+ natural killer cell distributions are heterogeneous in healthy adults and suppressed by azathioprine in patients with ANCA-associated vasculitides
por: Merkt, Wolfgang, et al.
Publicado: (2021)

CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1
por: Zeisbrich, Markus, et al.
Publicado: (2021)

ANCA-associated vasculitides in childhood
por: Garan, Diána, et al.
Publicado: (2011)

Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome)
por: Thiel, Jens, et al.
Publicado: (2013)

Overlap between dermatomyositis and ANCA vasculitides
por: Yuste, Claudia, et al.
Publicado: (2014)

Favourable outcome of acute hepatitis E infection in patients with ANCA-associated vasculitis
por: Zeisbrich, Markus, et al.
Publicado: (2022)

French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)
por: Terrier, Benjamin, et al.
Publicado: (2020)

Correction to: French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)
por: Terrier, Benjamin, et al.
Publicado: (2021)

T-helper cells as new players in ANCA-associated vasculitides
por: Abdulahad, Wayel H, et al.
Publicado: (2011)

Development of an ANCA-Associated Vasculitides Patient Registry in Greece
por: Thomas, Konstantinos, et al.
Publicado: (2020)

Therapeutic Complement Targeting in ANCA-Associated Vasculitides and Thrombotic Microangiopathy
por: Novikov, Pavel, et al.
Publicado: (2016)

Interest of Procalcitonin in ANCA Vasculitides for Differentiation between Flare and Infections
por: Poirot-Seynaeve, Xavier, et al.
Publicado: (2023)

Antineutrophil cytoplasmic antibody (ANCA)-associated autoimmune diseases induced by antithyroid drugs: comparison with idiopathic ANCA vasculitides
por: Bonaci-Nikolic, Branka, et al.
Publicado: (2005)

Plasma levels of M-CSF are increased in ANCA-associated vasculitides with active nephritis
por: Ramirez, Giuseppe A., et al.
Publicado: (2015)

T1 and T2 mapping for evaluation of myocardial involvement in patients with ANCA-associated vasculitides
por: Greulich, Simon, et al.
Publicado: (2017)

A rare case of spontaneous renal rupture caused by ANCA - associated vasculitides
por: Yu, Yongquan, et al.
Publicado: (2018)

ANCA-Associated Vasculitides and Hematologic Malignancies: Lessons from the Past and Future Perspectives
por: Folci, Marco, et al.
Publicado: (2019)

Is There Still a Role of Plasma Exchange in the Current Management of ANCA-Associated Vasculitides?
por: Toyoda, Task, et al.
Publicado: (2022)

Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides: Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity
por: Solans-Laqué, Roser, et al.
Publicado: (2017)

Respiratory tract infections and risk factors for infection in a cohort of 330 patients with axial spondyloarthritis or psoriatic arthritis
por: Frede, Natalie, et al.
Publicado: (2022)

Sleep behaviour differs in women and men with psoriatic arthritis and axial spondyloarthritis with impact on quality of life and depressive symptoms
por: Frede, Natalie, et al.
Publicado: (2023)

Development of Canadian Recommendations for the Management of ANCA-Associated Vasculitides: Results of the National Needs Assessment Questionnaire
por: Famorca, Leilani, et al.
Publicado: (2015)

CanVasc recommendations for the management of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides – Executive summary
por: McGeoch, Lucy, et al.
Publicado: (2015)

Genetic loci of Staphylococcus aureus associated with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides
por: Glasner, Corinna, et al.
Publicado: (2017)

Vasculitides
por: Weyand, Cornelia M., et al.
Publicado: (2008)

Microparticles expressing myeloperoxidase as potential biomarkers in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV)
por: Manojlovic, M., et al.
Publicado: (2020)

Impact of Cardiovascular Risk Factors on the Occurrence of Cardiovascular Events in Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitides
por: Roubille, Camille, et al.
Publicado: (2021)

The MRZ-Reaction and Specific Autoantibody Detection for Differentiation of ANA-Positive Multiple Sclerosis From Rheumatic Diseases With Cerebral Involvement
por: Venhoff, Nils, et al.
Publicado: (2019)

Case Report: Effective and Safe Treatment With Certolizumab Pegol in Pregnant Patients With Cogan’s Syndrome: A Report of Three Pregnancies in Two Patients
por: Venhoff, Nils, et al.
Publicado: (2021)

Serum calprotectin and renal function decline in ANCA-associated vasculitides: a post hoc analysis of MAINRITSAN trial
por: Romand, Xavier, et al.
Publicado: (2023)

Vasculitides in HIV Infection
por: Vega, Luis E., et al.
Publicado: (2020)

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab
por: van Dam, Laura S, et al.
Publicado: (2020)

Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients
por: Thomas, Konstantinos, et al.
Publicado: (2021)

Subclinical microvascular changes in ANCA-vasculitides: the role of optical coherence tomography angiography and nailfold capillaroscopy in the detection of disease-related damage
por: Triggianese, P, et al.
Publicado: (2023)

Successful Treatment of ANCA-Negative Wegener's Granulomatosis with Rituximab
por: Khan, Afsha, et al.
Publicado: (2010)

Biomarkers in Vasculitides of the Nervous System
por: Strunk, Daniel, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_q2ut3srmn2beob9p0r9b09v5vm